HOME >> BIOLOGY >> NEWS
Wistar Scientists Define Mechanism Of Action Used By Potential Magic Bullet In Cancer Treatment

Farnesyltransferase inhibitors (FTIs) are a relatively new class of nontoxic chemotherapeutic drugs that have an ability to target mutated oncogenes while bypassing normal cells; i.e., they may be the long sought-after magic bullet in cancer treatment.

In pre-clinical studies, FTIs have proven to control the growth of cancer cells and promote tumor regression. Little has been known, however, about how and why they work.

From their recent studies of FTIs, Wistar scientist, George Prendergast, Ph.D., and his Wistar research team made some surprising discoveries about their mechanism of action. Their findings appear today in the March issue of the scientific journal, Molecular and Cellular Biology.

The Wistar scientists had expected FTIs to interfere in some way with the activity of RAS, a cancer protein that tells cells when to start and stop dividing. Instead, they found that FTIs act in large part by affecting RHO, a class of proteins that regulate cell shape, survival and motility. Since RHO levels are elevated in many metastatic tumors, scientists have suspected for some time that RHO and cancer are in some way related. They had not known, however, if their relationship was causative or correlative.

One significant and unexpected finding of the study was that FTIs activate features of RHO by stimulating the production of an isoform with altered properties in the cell. In this way, FTIs make it possible for RHO to perform activities it could not previously perform.

An understanding of RHO alteration as the tumor principle targeted by FTIs will make it possible to make FTIs more effective, avoid drug resistance problems, and design other types of nontoxic antitumor drugs that target the same principle.


'"/>

Contact: Diana Cutshall
dcutshall@wistar.upenn.edu
215-898-3716
The Wistar Institute
17-Feb-1999


Page: 1

Related biology news :

1. Wistar-discovered antibody will help diagnose appendicitis
2. 2004 Wistar Institute Science Journalism Award winners announced
3. Call for Entries: The 2004 Wistar Institute Science Journalism Award
4. Wistar-developed antibody shows promise against brain tumors in Drexel trial
5. Wistar study offers new support for a histone code theory of gene regulation
6. Regeneration in the mammalian heart demonstrated by Wistar researchers
7. Wistar scientists add difficult-to-sequence stretches to human genome data
8. Wistar scientist receives award from National Cancer Institute
9. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
10. Wistar scientists find striking similarities between bacterial virus and human adenovirus
11. Wistar Institute scientists find key piece in gene regulation puzzle

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2019)... DIEGO (PRWEB) , ... October 09, 2019 , ... ... merger-acquisition of Nanosens Innovations, Inc., the creators of CRISPR-Chip™. Cardea first broke ... of their Early Access Program for the Genome Sensor™. Built with CRISPR-Chip technology, ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... the National Research Council of Canada (NRC) to create the Laboratory of ... technologies and in manufacturing, LIFT will offer a competitive capacity to accelerate ...
(Date:10/8/2019)... ... 07, 2019 , ... The future of medicine in the 21st century will ... living longer, healthier lives. But it will be up to each individual to make ... PhD, Chief Strategy Officer and Co-Founder of the Institute for Systems Biology and Senior ...
Breaking Biology News(10 mins):
(Date:10/8/2019)... ... October 08, 2019 , ... Today, Massachusetts stem cell ... lead development technology. Like the company’s precursor patent, approved in the U.S. in ... of tissue stem cells. Asymmetrex now markets the technology in the U.S. as ...
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the launch ... venture capital companies in Silicon Valley at a special Life Science showcase event ... be held at the JJ Lake Business Center located at 340 E. Middlefield Road ...
(Date:9/30/2019)... ... September 30, 2019 , ... The September 2019 edition of ... is now available online on the company’s global website. The Bridge features current ... fluorescence and imaging, and presents articles, scientific papers and news reports. , ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... has completed training and site qualification for clinical trial sites and physician investigators. ... screening of potential clinical trial participants. , Clinical trial sites are currently located ...
Breaking Biology Technology:
Cached News: